Employees Retirement System of Texas Has $42.99 Million Stake in Pfizer Inc. (PFE)
Employees Retirement System of Texas lifted its stake in Pfizer Inc. (NYSE:PFE) by 16.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,184,870 shares of the biopharmaceutical company’s stock after acquiring an additional 165,800 shares during the period. Pfizer makes up about 0.6% of Employees Retirement System of Texas’ holdings, making the stock its 25th largest holding. Employees Retirement System of Texas’ holdings in Pfizer were worth $42,987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently bought and sold shares of the company. HC Financial Advisors Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at about $2,685,000. Cetera Advisor Networks LLC increased its holdings in shares of Pfizer by 1.0% in the 1st quarter. Cetera Advisor Networks LLC now owns 333,601 shares of the biopharmaceutical company’s stock valued at $11,851,000 after purchasing an additional 3,365 shares during the period. Alphinity Investment Management Pty Ltd acquired a new position in shares of Pfizer in the 1st quarter valued at about $30,362,000. Glen Harbor Capital Management LLC increased its holdings in shares of Pfizer by 12.9% in the 1st quarter. Glen Harbor Capital Management LLC now owns 286,256 shares of the biopharmaceutical company’s stock valued at $10,159,000 after purchasing an additional 32,656 shares during the period. Finally, BlackRock Inc. increased its holdings in shares of Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after purchasing an additional 6,785,335 shares during the period. 68.64% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on PFE shares. Cantor Fitzgerald set a $53.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Thursday, November 8th. Bank of America increased their price objective on Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, August 1st. Societe Generale set a $43.00 price objective on Pfizer and gave the stock a “hold” rating in a report on Thursday, November 1st. JPMorgan Chase & Co. restated a “buy” rating and issued a $42.00 price objective on shares of Pfizer in a report on Thursday, August 23rd. Finally, Credit Suisse Group restated a “neutral” rating and issued a $40.00 price objective on shares of Pfizer in a report on Tuesday, October 30th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $42.67.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. The firm had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The company’s revenue was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.67 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 3 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a yield of 3.12%. Pfizer’s payout ratio is currently 51.32%.
In related news, major shareholder Pfizer Inc bought 55,556 shares of the firm’s stock in a transaction on Monday, October 15th. The stock was purchased at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the transaction, the insider now directly owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: How to Use the New Google Finance Tool
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.